All In Biotech

Drug Trial Radar · NCT07164443

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Engaging Agent Targeting Human Kallikrein 2, With or Without JNJ-87189401, a PSMA-CD28 Costimulatory Agent, Plus Best Supportive Care Versus Best Supportive Care for Late-line Metastatic Castration-resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,203 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,203

Planned (sponsor's estimate)

Start

Sep 2, 2025

Primary completion

Aug 18, 2028

Study completion Aug 18, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 with JNJ-87189401+BSC as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).

Conditions

  • Metastatic Castration-resistant Prostatic Neoplasms

Interventions

  • PasritamigBiological

    Pasritamig will be administrated through IV infusion.

  • PlaceboOther

    Placebo will be administrated through IV infusion.

  • Best Supportive Care (BSC)Drug

    BSC will be administered at the discretion of the treating physician.

  • JNJ-87189401Biological

    JNJ-87189401 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to 2 years and 8 months

Locations

176 sites in 17 countries. Site status is shown where the registry gives one.

  • University of California at San Diego

    La Jolla, California · Recruiting

  • Cedars Sinai Medical Center

    Los Angeles, California · Recruiting

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California · Recruiting

  • San Francisco VA Medical Center

    San Francisco, California · Recruiting

  • Rocky Mountain Cancer Centers

    Aurora, Colorado · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Colorado Clinical Research

    Lakewood, Colorado · Recruiting

  • Hartford Hospital

    Hartford, Connecticut · Recruiting

  • Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital

    Washington D.C., District of Columbia · Recruiting

  • Bay Pines VA Healthcare System

    Bay Pines, Florida · Recruiting

  • Florida Cancer Specialists & Research Institute

    Fort Myers, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa · Recruiting

  • Mission Cancer Blood

    Waukee, Iowa · Recruiting

  • East Jefferson General Hospital

    Metairie, Louisiana · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan Health System

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Cancer Detroit

    Detroit, Michigan · Recruiting

  • University Of Minnesota Medical Center

    Minneapolis, Minnesota · Recruiting

  • XCancer Omaha / Urology Cancer Center

    Omaha, Nebraska · Completed

  • NYU Langone Hospitals

    Brooklyn, New York · Recruiting

  • NYU Langone Hospital Long Island

    Mineola, New York · Recruiting

  • NYU Langone Health Laura and Isaac Perlmutter Cancer Center

    New York, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center

    Winston-Salem, North Carolina · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • University Hospital of Cleveland

    Cleveland, Ohio · Recruiting

  • Compass Oncology

    Portland, Oregon · Completed

  • Oregon Health And Science University

    Portland, Oregon · Recruiting

  • VA Portland Health Care System

    Portland, Oregon · Recruiting

  • Oregon Urology Institute

    Springfield, Oregon · Recruiting

  • MidLantic Urology

    Bala-Cynwyd, Pennsylvania · Recruiting

  • Keystone Urology Specialists

    Lancaster, Pennsylvania · Recruiting

  • Penn Medicine Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Cancer Centers

    Pittsburgh, Pennsylvania · Recruiting

  • Ralph H Johnson Veterans Hospital

    Charleston, South Carolina · Recruiting

  • Gibbs Cancer Center and Research Institute Pelham

    Greer, South Carolina · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.